Meta description: This report covers a new ClinicalTrials.gov record on PIMUN for reducing intermittent hypoxia in preterm infants, outlining regulatory implications and device performance expectations.
Regulatory watchers have a new item on the neonatal device calendar. A study titled Efficacy of PIMUN by Reducing Intermittent Hypoxia Events is recruiting to assess a device intended to reduce intermittent hypoxia events in preterm infants with apnea of prematurity and hypoxemia. The sponsor teams include Pontificia Universidad Catolica de Chile and Agencia Nacional de Investigacion y Desarrollo. This article explains what the trial seeks to measure and why regulators and clinicians should watch the results closely. Outcome measures listed in the record include brain near infrared spectroscopy monitoring, polysomnogram assessments, and investigations related to reactive oxygen species. The record signals ongoing collaboration between academic institutions and a national research agency to advance neonatal care with a device based approach.
What changed in this trial announcement?
The ClinicalTrials.gov record NCT07396103 identifies a preterm population with apnea of prematurity and hypoxemia and lists PIMUN as the intervention. It notes that the study uses noninvasive measurements including brain near infrared spectroscopy and polysomnography along with observations related to reactive oxygen species. Recruitment status is listed as recruiting and the sponsor is a collaboration between Pontificia Universidad Catolica de Chile and Agencia Nacional de Investigacion y Desarrollo. These details indicate an active effort to collect objective physiological data to support the device’s potential effect on intermittent hypoxia events.
How is the study designed to measure efficacy?
The record specifies interventions described as Brain NIRS, Polysomnogram, and Reactive Oxygen Species analysis. While the ClinicalTrials.gov entry does not provide full protocol specifics in this summary, the listed measures imply a focus on evaluating brain oxygenation and sleep related parameters in conjunction with oxidative stress markers. The described population and endpoints point to a regulatory interest in safety and performance signals for potential future device clearance or approval.
Why it matters for regulation and clinical practice?
From a regulatory perspective the trial aligns with expectations for neonatal device evaluation. The sponsor partners indicate academic and governmental support which could influence later submissions under the MDR framework. The combination of brain NIRS data and polysomnography provides objective evidence that regulators can review to assess device performance and safety in a vulnerable patient group. Observations on reactive oxygen species may inform safety assessments related to oxidative stress and device interaction with immature physiology.
What happens next?
As recruitment progresses results will become available to inform clinical practice and regulatory planning. If the trial demonstrates a favorable balance of efficacy and safety, the sponsor may prepare for later phase activities or regulatory communications. Clinicians and regulators should monitor the ClinicalTrials.gov page for updates and readouts that could influence how similar devices are evaluated in neonatal care.
FAQ
- 1. What is PIMUN?
PIMUN is the device studied in this trial to assess its ability to reduce intermittent hypoxia events in preterm infants with apnea of prematurity and hypoxemia.
- 2. Who sponsors the study?
The study is sponsored by Pontificia Universidad Catolica de Chile in collaboration with Agencia Nacional de Investigacion y Desarrollo.
- 3. Where can I find full trial details?
Full details are available on ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT07396103?term=medical+device.
Conclusion
The ongoing PIMUN trial represents a methodical step in evaluating a neonatal device intended to reduce intermittent hypoxia events in a high risk population. Regulatory teams should anticipate updates to the study record and prepare for potential future submissions that demonstrate device safety and performance in line with MDR Annex XIV expectations.
Disclaimer: This article is informational for professionals and is not legal advice. It should not be construed as regulatory guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07396103?term=medical+device